<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628172</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 11-0965</org_study_id>
    <nct_id>NCT01628172</nct_id>
  </id_info>
  <brief_title>Renal Sympathetic Denervation for the Management of Chronic Hypertension</brief_title>
  <acronym>RELIEF</acronym>
  <official_title>Renal Sympathetic Denervation for the Management of Chronic Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivek Reddy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the development of numerous drug therapies designed to treat hypertension, it remains
      a considerable and poorly managed health, social and economic burden. For various reasons,
      including the significant health care costs of treatment, there are estimates that up to 65%
      of hypertensive patients have untreated and/or uncontrolled blood pressure (BP).

      Aside from its impact on renal function, chronic hypertension significantly increases the
      risk for stroke, coronary artery disease, heart failure, and vascular disease. It is believed
      to be involved in the progression of cardiac arrhythmias. This link between hypertension and
      cardiovascular health has been well described; as has their combined effect on the aging and
      obesity-battling Western world.

      The recently published results of the Symplicity HTN-2 trial (Renal sympathetic denervation
      in patients with treatment resistant hypertension) establishing the therapeutic benefit of
      catheter-based renal sympathetic denervation for hypertension, have enormous potential for
      the management of a large and challenging patient population. The proposed, multicenter trial
      will attempt to confirm and expand on this promising data by conducting a double-blinded,
      placebo-controlled trial.

      Patients may qualify to participate in this research study if their doctor has determined
      that they have drug-resistant, chronic hypertension.

      Overall participation in this research study should be about 13 months which includes about 1
      month to start the study procedure and 12 months of follow-up after the study procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who qualify for the study and provide consent will undergo a renal angiogram in
      order to assess suitability for catheter-based renal sympathetic denervation. A renal
      angiogram is an x-ray study of the blood vessels in the kidney to evaluate for blockage, and
      abnormalities that could be affecting the blood supply to the kidney. It is performed by
      injecting contrast dye through a catheter (a tiny tube) into the blood vessels of the kidney.
      The study doctor will assess whether the renal arteries are suitable to receive
      catheter-based renal denervation.

      Both groups will receive sedation or anesthesia prior to the beginning of the procedure.

      The first group will undergo catheter-based sympathetic renal denervation. Renal Sympathetic
      Denervation is a procedure that uses a catheter probe inserted into the renal (kidney) artery
      that deactivates the nerves that are linked to high blood pressure.

      The second group will only receive renal angiography without the delivery of ablative energy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24-hour ambulatory BP</measure>
    <time_frame>baseline and at 6 months</time_frame>
    <description>Differences in 24-hour ambulatory blood pressure measurements recorded at baseline and at 6 months for each patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in office BP</measure>
    <time_frame>baseline, 6 months, and 12 months</time_frame>
    <description>Difference in office blood pressure measurements at 6 months and at 12 months as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in ambulatory BP</measure>
    <time_frame>baseline and at 12 months</time_frame>
    <description>Difference in 24 hour ambulatory blood pressure measurements at 12 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal artery dimensions</measure>
    <time_frame>baseline and at 6 months</time_frame>
    <description>Change in renal artery dimensions at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>baseline and at 6 months</time_frame>
    <description>Differences in creatinine measurements recorded at baseline and at 6 months for each patient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Uncontrolled Hypertension</condition>
  <arm_group>
    <arm_group_label>Biosense Webster Celcius Thermacool catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects will undergo catheter-based sympathetic renal denervation. Ablation arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>renal angiogram only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control Group: Control arm will not receive intervention but will be followed for 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biosense Webster Celcius Thermacool catheter</intervention_name>
    <description>catheter-based sympathetic renal denervation</description>
    <arm_group_label>Biosense Webster Celcius Thermacool catheter</arm_group_label>
    <other_name>sympathetic renal denervation</other_name>
    <other_name>Ablation arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 and ≤ 85 years of age

          -  Uncontrolled hypertension (defined as SBP ≥ 140 mmHg during 24Hr Ambulatory BP
             monitoring)

          -  Current treatment with ≥ 3 anti-hypertensive drugs (including at least one diuretic)

          -  Accessibility of renal vasculature

          -  Ability to understand the requirements of the study

          -  Willingness to adhere to study restrictions and comply with all post-procedural
             follow-up requirements

        Exclusion Criteria:

          -  Secondary cause of hypertension

          -  White coat hypertension

          -  Estimated GFR &lt; 45

          -  Type 1 Diabetes

          -  Known renovascular abnormalities (eg, renal artery stenosis, previous renal artery
             stenting or angioplasty)

          -  Life expectancy &lt;1 year for any medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Reddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fakultní nemocnice u sv. Anny v Brně</name>
      <address>
        <city>Brno</city>
        <zip>53, 656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <reference>
    <citation>Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009 Apr 11;373(9671):1275-81. doi: 10.1016/S0140-6736(09)60566-3. Epub 2009 Mar 28.</citation>
    <PMID>19332353</PMID>
  </reference>
  <reference>
    <citation>Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009 Jan 27;119(3):e21-181. doi: 10.1161/CIRCULATIONAHA.108.191261. Epub 2008 Dec 15. Erratum in: Circulation. 2011 Oct 18;124(16):e424. Circulation. 2010 Jul 6;122(1):e11. Circulation. 2009 Jan 27;119(3):e182.</citation>
    <PMID>19075105</PMID>
  </reference>
  <reference>
    <citation>Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23.</citation>
    <PMID>15652604</PMID>
  </reference>
  <reference>
    <citation>Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008 Nov 25;52(22):1749-57. doi: 10.1016/j.jacc.2008.08.036. Review.</citation>
    <PMID>19022154</PMID>
  </reference>
  <reference>
    <citation>Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008 Nov;52(5):818-27. doi: 10.1161/HYPERTENSIONAHA.108.113357. Epub 2008 Oct 13.</citation>
    <PMID>18852389</PMID>
  </reference>
  <reference>
    <citation>Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 Jun 24;117(25):e510-26. doi: 10.1161/CIRCULATIONAHA.108.189141.</citation>
    <PMID>18574054</PMID>
  </reference>
  <reference>
    <citation>DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens. 2002 Mar;11(2):197-200. Review.</citation>
    <PMID>11856913</PMID>
  </reference>
  <reference>
    <citation>DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997 Jan;77(1):75-197. Review.</citation>
    <PMID>9016301</PMID>
  </reference>
  <reference>
    <citation>Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988 Jan;11(1):3-20. Review.</citation>
    <PMID>2828236</PMID>
  </reference>
  <reference>
    <citation>Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension. 2004 Feb;43(2):169-75. Epub 2003 Nov 10.</citation>
    <PMID>14610101</PMID>
  </reference>
  <reference>
    <citation>MORRISSEY DM, BROOKES VS, COOKE WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953 Feb 28;1(6757):403-8.</citation>
    <PMID>13024041</PMID>
  </reference>
  <reference>
    <citation>SMITHWICK RH, THOMPSON JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953 Aug 15;152(16):1501-4.</citation>
    <PMID>13061307</PMID>
  </reference>
  <reference>
    <citation>EVELYN KA, SINGH MM, CHAPMAN WP, PERERA GA, THALER H. Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension. A ten-year study of 100 sympathectomized patients compared with individually matched, symptomatically treated control subjects. Am J Med. 1960 Feb;28:188-221.</citation>
    <PMID>13821037</PMID>
  </reference>
  <reference>
    <citation>Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70.</citation>
    <PMID>10075613</PMID>
  </reference>
  <reference>
    <citation>Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42(6):1206-52. Epub 2003 Dec 1.</citation>
    <PMID>14656957</PMID>
  </reference>
  <reference>
    <citation>Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M, Cuspidi C, Facchetti R, Bolla G, Mancia G. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension. 2008 Nov;52(5):925-31. doi: 10.1161/HYPERTENSIONAHA.108.116368. Epub 2008 Sep 8.</citation>
    <PMID>18779438</PMID>
  </reference>
  <reference>
    <citation>DiBona GF. Renal innervation and denervation: lessons from renal transplantation reconsidered. Artif Organs. 1987 Dec;11(6):457-62. Review.</citation>
    <PMID>3326559</PMID>
  </reference>
  <reference>
    <citation>O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. Lancet. 1988 Aug 13;2(8607):397.</citation>
    <PMID>2899801</PMID>
  </reference>
  <reference>
    <citation>Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002 Oct 8;106(15):1974-9.</citation>
    <PMID>12370222</PMID>
  </reference>
  <reference>
    <citation>Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, Esler MD, Lambert GW. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009 May;20(5):933-9. doi: 10.1681/ASN.2008040402. Epub 2008 Sep 17. Review.</citation>
    <PMID>18799718</PMID>
  </reference>
  <reference>
    <citation>DiBona GF. Neural control of the kidney: past, present, and future. Hypertension. 2003 Mar;41(3 Pt 2):621-4. Epub 2002 Dec 16.</citation>
    <PMID>12623969</PMID>
  </reference>
  <reference>
    <citation>Fagius J. Sympathetic nerve activity in metabolic control--some basic concepts. Acta Physiol Scand. 2003 Mar;177(3):337-43. Review.</citation>
    <PMID>12609004</PMID>
  </reference>
  <reference>
    <citation>Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004 Apr;43(4):699-706. Epub 2004 Feb 23. Review.</citation>
    <PMID>14981063</PMID>
  </reference>
  <reference>
    <citation>Luippold G, Beilharz M, Mühlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant. 2004 Feb;19(2):342-7.</citation>
    <PMID>14736957</PMID>
  </reference>
  <reference>
    <citation>Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens. 2002 Aug;15(8):717-24.</citation>
    <PMID>12160195</PMID>
  </reference>
  <reference>
    <citation>Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis. 1995 Nov;26(5):861-5.</citation>
    <PMID>7485145</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2012</study_first_submitted>
  <study_first_submitted_qc>June 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Vivek Reddy</investigator_full_name>
    <investigator_title>Director Cardiac Arrhythmia Service, Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>renal sympathetic denervation</keyword>
  <keyword>renal catheter ablation</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

